| gap-test-5dc8476a | Test Gap | open | 0.50 | 0.00 | 2026-04-11 | 0 | | test |
| gap-pubmed-20260411- | What is the causal relationship between endothelial dysfunction and microglial a | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does KMT2A histone modification mechanistically link AGE receptor signaling | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms link retinoic acid-induced mitophagy to the observed c | resolved | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does tyrosine β-hydroxylase protein expression increase while its gene expre | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do Cdk5 and PKA pathways interact to control striatal plasticity bidirection | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms allow Cdk5 inhibition to unmask LTP in striatal neuron | open | 0.82 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | Why does Cdk5 immunostaining increase without corresponding protein level change | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do PROTAC-mediated Keap1 degradation kinetics compare to direct PPI inhibiti | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What determines tissue-specific efficacy of Keap1-Nrf2 inhibitors across differe | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does Nptx2-mediated complement regulation differ between physiological and p | open | 0.73 | 0.00 | 2026-04-11 | 0 | | synaptic-biology |
| gap-pubmed-20260411- | Why are Nptx2 levels reduced in FTD patients and what drives this reduction? | open | 0.78 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the molecular mechanism by which Nptx2 binding to C1q inhibits complemen | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the essential research directions needed to advance MIF nuclease inhibi | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why is MIF nuclease activity specifically pathogenic while other MIF enzymatic a | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does MIF nuclease activity mechanistically drive parthanatos-mediated neuron | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What extended timeframes are needed to detect latent AD-related sleep-cognition | open | 0.74 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why don't APOE ε4 and AD biomarkers modulate sleep-cognition relationships in pr | resolved | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms explain why deviations from individual sleep patterns impair nex | resolved | 0.77 | 0.00 | 2026-04-11 | 0 | | sleep-neuroscience |
| gap-pubmed-20260411- | Why have previous in vitro studies failed to replicate disease-relevant α-synucl | resolved | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which specific CSF molecular components are essential for maintaining disease-re | partially_addressed | 0.87 | 0.00 | 2026-04-11 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms cause aCSF-formed α-synuclein fibrils to lose stabilit | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What mechanisms underlie the high frequency of GBA1 variants (7.7%) in North Ame | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do 9.1% of Parkinson's patients without traditional risk factors carry patho | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do autonomic nerve networks integrate with cytokine signaling to coordinate | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What are the specific molecular mechanisms by which neuroinflammation bidirectio | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What refined biomarkers beyond p16INK4a can accurately measure brain senescence | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does ABT-263 with limited brain penetrance effectively reduce AD neuropathol | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do senolytics reduce AD pathology despite low p16INK4a-associated senescence | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How can targeted inhibitor use be optimized for maximum efficacy in pediatric lo | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | What are the long-term toxicities of targeted inhibitors in pediatric low-grade | open | 0.85 | 0.00 | 2026-04-11 | 0 | | neuro-oncology |
| gap-pubmed-20260411- | How do altered striatal EVs contribute to HD progression and inter-cellular comm | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms enable motor skill learning to restore EV content and | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the optimal timing window for unfolded protein response-targeted interve | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why do observational studies fail to detect disease-modifying effects that exper | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What is the minimum effective dose of trazodone required for disease-modifying e | investigating | 0.87 | 0.00 | 2026-04-11 | 1 | 2026-04-25 | neurodegeneration |
| gap-pubmed-20260411- | What determines the tissue-specific and temporal dynamics of H2-mediated neuropr | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does H2 specifically promote NRF2 nuclear translocation at the molecular lev | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Which of quercetin's multiple target interactions is most critical for protectio | open | 0.75 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does quercetin's binding to ChAt, TNF, IL-6, and IL-1β translate to neuropro | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | Does the cathepsin B-mediated amyloidogenic pathway occur in other lysosomal sto | open | 0.84 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does cathepsin B specifically process APP to generate the 16-kDa C-terminal | open | 0.83 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | What molecular mechanisms drive cathepsin B leakage from lysosomes to cytoplasm | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | Why does AS-II suppress rather than activate the β-catenin/Id2/MBP axis for remy | open | 0.76 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How does p75NTR binding by AS-II suppress β-catenin/Id2/MBP signaling to promote | open | 0.82 | 0.00 | 2026-04-11 | 0 | | neurodegeneration |
| gap-pubmed-20260411- | How do protein-protein interaction networks mediate the causal effects of distan | open | 0.76 | 0.00 | 2026-04-11 | 0 | | systems-biology |
| gap-pubmed-20260411- | What are the specific post-transcriptional mechanisms that mediate distant prote | open | 0.77 | 0.00 | 2026-04-11 | 0 | | molecular-genetics |
| gap-pubmed-20260411- | What determines the temporal window for effective NLRP3/caspase-1 inhibition in | resolved | 0.84 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | How does microglial pyroptosis specifically recruit peripheral leukocytes to the | open | 0.79 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |
| gap-pubmed-20260411- | What upstream signals trigger NLRP3 inflammasome activation in microglia followi | open | 0.80 | 0.00 | 2026-04-11 | 0 | | neuroinflammation |